TP53 and cancer: While APR-246 was initially characterized as a reactivator of mutant p53 function, its p53-independent mechanisms of action have garnered increasing attention and growing evidence suggests that APR-246 exerts its anti-cancer effects through p53-independent mechanisms as well [62–64] ().